GSK's Dierdre P. Connelly makes a promise

Our company is facing a changing health care market that demands higher-quality care, lower costs and better outcomes. As part of rethinking and redesigning our commercial model in the United States, we have revamped our procedures for training, evaluating and compensating our 5,000 sales people.

This was under way when, last year, the company paid $3 billion in fines to the federal government because it had earlier promoted some antidepressants for unapproved uses and failed to report the status of studies about our diabetes drug. We are committed to ensuring that this never happens again.

http://www.nytimes.com/2013/07/07/jobs/a-glaxo-executive-seeing-through-a-sales-reps-eyes.html?ref=glaxosmithklineplc